Dermata Therapeutics (DRMA) Short Interest Ratio & Short Volume $0.82 +0.00 (+0.43%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dermata Therapeutics Short Interest DataDermata Therapeutics (DRMA) has a short interest of 121,000 shares, representing 2.73% of the float (the number of shares available for trading by the public). This marks a -84.29% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.16 million shares to cover all short positions.Current Short Interest121,000 sharesPrevious Short Interest770,100 sharesChange Vs. Previous Month-84.29%Dollar Volume Sold Short$94,246.90Short Interest Ratio0.1 Days to CoverLast Record DateApril 15, 2025Outstanding Shares6,033,000 sharesFloat Size4,430,000 sharesShort Percent of Float2.73%Today's Trading Volume1,827 sharesAverage Trading Volume1,163,594 sharesToday's Volume Vs. Average0% Short Selling Dermata Therapeutics? Sign up to receive the latest short interest report for Dermata Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDRMA Short Interest Over TimeDRMA Days to Cover Over TimeDRMA Percentage of Float Shorted Over Time Dermata Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2025121,000 shares $94,246.90 -84.3%2.7%0.1 $0.78 3/31/2025770,100 shares $831,708.00 +307.9%19.3%0.5 $1.08 3/15/2025188,800 shares $224,672.00 -23.8%4.7%0.5 $1.19 2/28/2025247,700 shares $282,378.00 -10.9%15.2%0.5 $1.14 2/15/2025278,000 shares $330,820.00 -5.5%44.9%0.6 $1.19 1/31/2025294,200 shares $361,866.00 +112.9%47.5%0.6 $1.23 1/15/2025138,200 shares $192,098.00 -3.3%15.7%0.3 $1.39 12/31/2024142,900 shares $192,915.00 +11.3%7.1%0.5 $1.35 12/15/2024128,400 shares $139,956.00 +125.7%6.4%0.4 $1.09 11/30/202456,900 shares $64,183.20 -36.9%2.9%0.1 $1.13 Get the Latest News and Ratings for DRMA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/202490,200 shares $101,033.02 -3.7%6.1%0.2 $1.12 10/31/202493,700 shares $118,999.00 +228.8%6.3%0.2 $1.27 10/15/202428,500 shares $36,765.00 -58.8%1.9%0 $1.29 9/30/202469,100 shares $113,324.00 +558.1%4.7%0 $1.64 9/15/202410,500 shares $16,590.00 -53.5%0.7%0 $1.58 8/31/202422,600 shares $39,324.00 -49.9%1.8%0 $1.74 8/15/202445,100 shares $92,906.00 -12.9%3.6%0 $2.06 7/31/202451,800 shares $89,096.00 -1.5%8.0%0 $1.72 7/15/202452,600 shares $115,194.00 +141.3%8.1%0 $2.19 6/30/202421,800 shares $52,102.00 +6.9%3.4%0.6 $2.39 6/15/202420,400 shares $52,073.04 -20.0%4.9%0.7 $2.55 5/31/202425,500 shares $97,920.00 +318.0%6.1%1.5 $3.84 5/15/20246,100 shares $30,195.00 -92.4%1.5%0.4 $4.95 4/30/202480,400 shares $26,298.84 +3.6%1.3%0.7 $0.33 4/15/202477,600 shares $23,295.52 -23.8%1.2%0.5 $0.30 3/31/2024101,800 shares $41,819.44 +42.6%1.7%0.2 $0.41 3/15/202471,400 shares $28,417.20 -0.8%2.1%0.1 $0.40 2/29/202472,000 shares $33,048.00 -57.5%2.5%0.1 $0.46 2/15/2024169,500 shares $78,817.50 -39.3%6.0%0.2 $0.47 1/31/2024279,400 shares $137,045.70 -5.5%9.9%0.3 $0.49 1/15/2024295,600 shares $159,328.40 +1,032.6%10.5%0.3 $0.54 12/31/202326,100 shares $15,921.00 -25.9%0.9%0 $0.61 12/15/202335,200 shares $23,936.00 -67.7%1.3%0.2 $0.68 11/30/2023108,800 shares $81,099.52 +57.7%3.9%0.5 $0.75 11/15/202369,000 shares $44,988.00 +156.5%2.5%0.2 $0.65 10/31/202326,900 shares $15,653.11 -34.6%1.0%0.2 $0.58 10/15/202341,100 shares $30,825.00 -42.3%1.5%0.3 $0.75 9/30/202371,200 shares $75,472.00 -29.1%2.6%0.5 $1.06 9/15/2023100,400 shares $117,468.00 +16,633.3%3.6%0.6 $1.17 8/31/2023600 shares $744.00 -95.8%0.0%0 $1.24Trump to solve American wealth loss? (Ad)Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.If you missed out on a bitcoin fortune, this could be your second chance. A brief “wealth window” is 8/15/202314,400 shares $16,992.00 -10.0%0.5%0.1 $1.18 7/31/202316,000 shares $20,800.00 -66.3%0.8%0 $1.30 7/15/202347,500 shares $74,575.00 -42.5%2.3%0.1 $1.57 6/30/202382,600 shares $136,290.00 +17.5%4.0%0 $1.65 6/15/202370,300 shares $130,055.00 +221.0%3.6%0 $1.85 5/31/202321,900 shares $35,040.00 -68.5%1.7%0 $1.60 5/15/202369,600 shares $179,568.00 +10.3%4.1%0 $2.58 4/30/202363,100 shares $103,484.00 +248.6%0.7%0 $1.64 4/15/202318,100 shares $22,806.00 -40.9%0.2%0 $1.26 3/31/202330,600 shares $39,474.00 +155.0%0.4%0 $1.29 3/15/202312,000 shares $33,840.00 -93.8%0.2%0 $2.82 2/28/2023194,000 shares $50,440.00 -0.2%2.4%0.1 $0.26 2/15/2023194,400 shares $56,084.40 -42.2%2.4%0.1 $0.29 1/31/2023336,100 shares $92,057.79 +36.2%4.2%0.2 $0.27 1/15/2023246,800 shares $67,277.68 +121.0%3.1%0.1 $0.27 12/30/2022111,700 shares $45,685.30 -5.7%1.4%0.1 $0.41 12/15/2022118,500 shares $23,024.55 +8.2%1.5%0.2 $0.19 11/30/2022109,500 shares $70,616.55 -25.8%1.5%0.4 $0.64 11/15/2022147,600 shares $98,892.00 -18.6%2.1%0.6 $0.67 10/31/2022181,300 shares $119,748.65 +129.5%3.0%0.5 $0.66 10/15/202279,000 shares $56,090.00 +62.6%1.3%0.2 $0.71 9/30/202248,600 shares $25,276.86 +21.5%0.8%0.1 $0.52 9/15/202240,000 shares $25,672.00 -54.3%0.7%0 $0.64 8/31/202287,500 shares $49,875.00 +154.4%1.6%0.1 $0.57 8/15/202234,400 shares $23,392.00 -52.6%0.6%0 $0.68 7/31/202272,600 shares $42,195.12 +30.3%1.6%0.1 $0.58 7/15/202255,700 shares $41,218.00 -78.6%1.2%0 $0.74 6/30/2022260,000 shares $169,026.00 +3,413.5%5.6%0.2 $0.65 6/15/20227,400 shares $3,981.20 -82.6%0.2%0.1 $0.54 5/31/202242,600 shares $33,236.52 +138.0%1.0%0.4 $0.78 5/15/202217,900 shares $14,749.60 -53.0%0.4%0.2 $0.82 4/30/202238,100 shares $39,243.00 -85.4%0.9%0.1 $1.03 4/15/2022261,400 shares $299,303.00 -15.5%6.1%0.5 $1.15 3/31/2022309,500 shares $386,875.00 +1.1%N/A0.5 $1.25 3/15/2022306,200 shares $286,358.24 -23.1%7.0%0.5 $0.94 2/28/2022398,000 shares $489,540.00 -48.2%9.2%0.7 $1.23 2/15/2022768,100 shares $898,677.00 +477.5%17.7%1.3 $1.17 1/31/2022133,000 shares $299,250.00 +56.7%3.1%0.6 $2.25 1/15/202284,900 shares $131,595.00 +69.5%N/A0.3 $1.55 12/31/202150,100 shares $87,174.00 No Change1.2%0.2 $1.74 DRMA Short Interest - Frequently Asked Questions What is Dermata Therapeutics' current short interest? Short interest is the volume of Dermata Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 121,000 shares of DRMA short. 2.73% of Dermata Therapeutics' shares are currently sold short. Learn More on Dermata Therapeutics' current short interest. What is a good short interest percentage for Dermata Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.73% of Dermata Therapeutics' floating shares are currently sold short. Is Dermata Therapeutics' short interest increasing or decreasing? Dermata Therapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 121,000 shares, a decrease of 84.3% from the previous total of 770,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Dermata Therapeutics' float size? Dermata Therapeutics currently has issued a total of 6,033,000 shares. Some of Dermata Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Dermata Therapeutics currently has a public float of 4,430,000 shares. How does Dermata Therapeutics' short interest compare to its competitors? 2.73% of Dermata Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Dermata Therapeutics: Chemomab Therapeutics Ltd. (0.81%), Edesa Biotech, Inc. (0.90%), Sol-Gel Technologies Ltd. (0.50%), Equillium, Inc. (1.10%), Lipocine Inc. (1.39%), Cingulate Inc. (4.50%), Unity Biotechnology, Inc. (4.83%), Bullfrog AI Holdings, Inc. (7.34%), BriaCell Therapeutics Corp. (5.96%), Leap Therapeutics, Inc. (11.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Dermata Therapeutics stock? Short selling DRMA is an investing strategy that aims to generate trading profit from Dermata Therapeutics as its price is falling. DRMA shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Dermata Therapeutics? A short squeeze for Dermata Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of DRMA, which in turn drives the price of the stock up even further. How often is Dermata Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DRMA, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Chemomab Therapeutics Short Squeeze Edesa Biotech Short Squeeze Sol-Gel Technologies Short Squeeze Equillium Short Squeeze Lipocine Short Squeeze Cingulate Short Squeeze Unity Biotechnology Short Squeeze Bullfrog AI Short Squeeze BriaCell Therapeutics Short Squeeze Leap Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DRMA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.